MOLN - Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations | Benzinga
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that it will issue its fourth quarter and full year financial results for 2023 on March 14, which will be followed by a conference call the next day to discuss the results.
Molecular Partners' Chief Executive Officer Patrick Amstutz will also present at the 44th Annual Cowen Health Care Conference taking place in Boston, MA, and will participate in the Leerink Global Biopharma Conference taking place in Miami, FL along with other members of the Company's leadership team. Please see details below:
Cowen Health Care Conference Presentation Details:
Novel Oncology Targets Corporate Panel Discussion:
Time: Tuesday, March 5, 2024 at 9:10 am ET (3:10 pm CET)
Fireside Chat Q&A:
Time: Wednesday, March 6, 2024 at 10:30 am ET (4:30 pm CET)
Webcasts of the Panel discussion as well as the fireside chat can be accessed through the investors section of the Molecular Partners website.
Leerink Global Biopharma Conference Participation Details:
Date: March 11-13, 2024
Location: Miami, FL
Full Year 2023 Results Release Date and Time:
March 14, 2024 at 4:00 pm ET (9:00 pm CET)
Full Year 2023 Conference Call Details:
March 15, 2024 at 8:00 am ET (1:00 pm CET)
The full year 2023 results presentation will also be webcast live and will be made available on the Company's website under the investors section. The replay will be available for 90 days following the presentation.
In order to register for the full year 2023 conference call on March 15, 8:00 am ET / 1:00 pm CET, please dial the following numbers ...